Announcements Trials
Browse Landscape

Phase

Phase 4 5Phase 3 5Phase 2 3

Status

Terminated 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Pancreatic Ductal Adenocarcinoma 1Glioma 1Behavior, Addictive 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Escitalopram × Clear all
NCT03728673 2026-04-17

A Study Utilizing Escitalopram in Glioma Patients

University of Nebraska

Phase 2 Recruiting
20 enrolled
CNS

Glioma

NCT05289830 2025-12-10

Escitalopram to Placebo in Patients With Localized Pancreatic Cancer

Case Comprehensive Cancer Center

Phase 2 Terminated
4 enrolled 10 charts
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT03010761 2019-07-24

Establishment of Cessation Therapy by Clinical Trials for Subjects With Betel-quid Dependence and Oral Pre-cancer

China Medical University Hospital

Phase 2 Terminated
90 enrolled

Behavior, Addictive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡